NeuCyte is an early-stage biotechnology company solely focused on neurological diseases. With the expertise on advancing the drug discovery process by using cell based target-identification and drug-discovery platforms, NeuCyte puts an emphasis on the biology insight of the disorders to develop novel drugs that truly address the altered biological state of the patients.
Our technology accelerates the lead drug identification and optimization process. NeuCyte’s unique human neural platform allows for the evaluation of human specific neural phenotypes that are not identifiable in traditional animal models. This allows for a more reliable predictor of drug efficacy and potential neurotoxicity.
Meet the Team
NeuCyte’s all-star staff and scientific advisory board are comprised of some of the top stem cell biologist and neuroscientist in the world. The vast knowledge from our team gives us an unrivaled advantage to address the unmet needs of patients with neurological disorders.
NeuCyte’s mission is to improve the lives of those affected by Central Nervous System (CNS) related disorders by developing better translatable solutions to accelerate and optimize CNS drug discovery.
Scientific Advisory Board
Co-Founder and SAB Chairman,
Professor, Stanford University School of Medicine,
Director, Cell Biology, Conrad Prebys Center for Chemical Genomics at Sanford Burnham Medical Research Institute
Director, Stem Cell Services and Technologies at RUCDR Infinite Biologics
Distinguished Professor in Biochemistry
and Molecular Medicine, University of
California at Davis
Professor of Environmental Toxicology, The Heinrich Heine University of Düsseldorf
Why Partner with NeuCyte?
NeuCyte has created a proprietary platform based on iPSC technology that enables translatable neuroscience. Solely focusing on neurological disorders, NeuCyte has put together a world-class scientific team of experts for extracting and understanding human disease related phenotypes for target identification.
By harnessing the power of the SynFire® neural cells, our platform allows for in vitro modeling of neurological disorders using disease relevant cells, as well as for phenotypic and target-based drug screens.
NeuCyte is open to exploring strategic partnerships to accelerate our current drug discovery programs and to expand the use of our platform beyond our internal R&D programs. We are interested in pursuing other neurological disease models, technologies and drug candidates that are consistent with NeuCyte’s core mission of helping those suffering from neuro related illnesses.
For more information, please contact us at